The National Law Review2d
Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration
Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove ...
ETF Daily News3d
Zymeworks (ZYME) Expected to Announce Earnings on Wednesday
In other Zymeworks news, Director Ecor1 Capital, Llc bought 11,958 shares of the firm’s stock in a transaction dated Tuesday, December 24th. The stock was acquired at an average cost of $14.12 ...
Yahoo Finance10d
Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors
VANCOUVER, British Columbia, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage ...
Nasdaq2d
Zymeworks Receives $14 Million Cash Research Milestone Payment From GSK
(RTTNews) - Zymeworks Inc. (ZYME), Wednesday announced that the company has received a cash research milestone payment of $14 million from GSK plc (GSK) associated with a previous milestone.
Jazz Pharmaceuticals: Decent 2025 Outlook, Extended Timeline For Zanidatamab
Jazz Pharmaceuticals ended 2024 on a strong note, beating analyst estimates. I continue to see Jazz stock as a valuation ...
Hosted on MSN1mon
EcoR1 Capital buys $1.96 million in Zymeworks stock
EcoR1's involvement with Zymeworks extends beyond stock ownership, as Scott Platshon, an employee of EcoR1, serves as a director on Zymeworks' board. Platshon was nominated for the board by EcoR1 ...
Nasdaq3d
Zymeworks Inc. Announces Participation in Upcoming Investor Conferences in March 2025
Zymeworks Inc., a clinical-stage biotechnology company focused on developing innovative biotherapeutics for challenging diseases such as cancer, inflammation, and autoimmune disorders, has ...